- Home
- YY vs DYN Comparison
YY vs DYN Comparison
Compare YY & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YY
- DYN
- Stock Information
- Founded
- YY 2005
- DYN 1984
- Country
- YY Singapore
- DYN United States
- Employees
- YY N/A
- DYN N/A
- Industry
- YY EDP Services
- DYN Medicinal Chemicals and Botanical Products
- Sector
- YY Technology
- DYN Health Care
- Exchange
- YY Nasdaq
- DYN Nasdaq
- Market Cap
- YY 2.2B
- DYN 2.6B
- IPO Year
- YY 2012
- DYN 2020
- Fundamental
- Price
- YY $45.34
- DYN $13.96
- Analyst Decision
- YY Hold
- DYN Strong Buy
- Analyst Count
- YY 3
- DYN 10
- Target Price
- YY $35.00
- DYN $50.78
- AVG Volume (30 Days)
- YY 460.7K
- DYN 2.9M
- Earning Date
- YY 03-17-2025
- DYN 03-04-2025
- Dividend Yield
- YY 1.80%
- DYN N/A
- EPS Growth
- YY N/A
- DYN N/A
- EPS
- YY 3.11
- DYN N/A
- Revenue
- YY $2,258,181,000.00
- DYN N/A
- Revenue This Year
- YY $0.76
- DYN N/A
- Revenue Next Year
- YY $1.88
- DYN N/A
- P/E Ratio
- YY $14.56
- DYN N/A
- Revenue Growth
- YY N/A
- DYN N/A
- 52 Week Low
- YY $27.88
- DYN $13.24
- 52 Week High
- YY $47.01
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- YY 60.43
- DYN 27.41
- Support Level
- YY $44.02
- DYN $13.24
- Resistance Level
- YY $45.84
- DYN $14.51
- Average True Range (ATR)
- YY 1.55
- DYN 1.16
- MACD
- YY 0.26
- DYN 0.08
- Stochastic Oscillator
- YY 74.09
- DYN 15.96
About YY JOYY Inc.
JOYY Inc is a global technology company offering comprehensive innovation capabilities. The company enables users to interact with others in real time. The group is actively exploring and expanding its global commerce Software-as-a-Service and solutions business. JOYY emphasizes technological innovation and is recognized in the industry for its significant number of patent applications and licenses.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.